Price History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Trend
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Price Action
Support & Resistance Levels
Volume Analysis
Stop Loss Levels
Fixed Risk
Technical Levels
Moving Averages
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Sep '25 |
|---|---|---|---|---|
| Revenue | ₹43.4 Cr | ₹50.2 Cr | ₹52.7 Cr | ₹57.6 Cr |
| Net Profit | ₹4.5 Cr | ₹5.8 Cr | ₹4.7 Cr | ₹4.5 Cr |
| EPS | ₹2.08 | — | ₹2.11 | ₹2.03 |
| Operating Profit | ₹12 Cr | ₹15.3 Cr | ₹13.1 Cr | ₹12.6 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 13 Sept 2024 | Annual General Meeting | AGM |
| 14 Sept 2023 | Annual General Meeting | AGM |
| 12 Sept 2022 | Annual General Meeting | AGM |
| 16 Sept 2021 | Annual General Meeting | AGM |
| 16 Sept 2020 | Annual General Meeting | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for SAKAR
View All
Sakar Healthcare partners with Zydus Lifesciences for GCC Markets
Sakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks the company's 40th global agreement in the anti-cancer segment. Sakar Healthcare is expanding its international oncology business and strengthening its presence in emerging markets. The company is also progressing with regulatory filings and approvals in highly regulated markets.
Multibagger healthcare stock retraces from near record high. Do you own?
Sakar Healthcare stock had touched a record high of ₹829.60 in the last trading session, while its 52-week low stands at ₹306, hit on 23 May last year. NSE data shows that 1.55 lakh shares of the healthcare firm were traded today.
Sakar Healthcare Q4 profit up 91% at Rs 11.02 crore
Sakar Healthcare announced strong financial results for the January-March quarter of 2025-26. Net profit surged by 91 percent to Rs 11.02 crore. Revenue from operations increased by 42 percent to Rs 71.09 crore. For the full fiscal year, net profit rose 74 percent to Rs 30.48 crore. Revenue jumped 42 percent to Rs 251.73 crore.